We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Date    Patent No Sample Clauses

Date    Patent NoIssue Date Status Owner
Date    Patent No. EXP. DATE ------- ----------- ----------- --------- Tanganyika 30.09.97 2533 01.12.09 Trinidad+Tobago 14.11.95 78/95 01.12.09 USA 19.05.98 5753627 06.06.15 USA 07.07.98 5776894 07.07.15 * Saudi Arabia: patent application still pending, filing number 95160495 EXHIBIT 1A (CONTINUATION) 2. Additional Use Patent (118-7595)
Date    Patent No. EXP. DATE ------- ---------- ----------- ----------- ------------ --------- Argentina 05.09.95 333413 22.03.04 AR256010M 05.09.15 Australia 04.09.95 30414/95 24.06.99 703057 04.09.15 Austria 04.00.00 00000005.4 07.03.01 714911 04.09.15 Belgium 04.09.95 95810545.4 07.03.01 714911 04.09.15 Brazil 05.09.95 PI9503936-8 22.06.04 PI9503936-8 05.09.15 Canada 05.09.95 2157530 05.09.15 Chile 05.09.95 1351/95 10.10.00 40732 10.10.15 China 05.09.95 115610/95 19.01.05 ZL95115610.1 05.09.15 Colombia 05.09.00 00000003 30.07.01 27134 05.09.15 Czech Republic 04.09.95 PV1995-2263 14.06.00 287012 04.09.15 Denmark 04.09.95 95810545.4 07.03.01 714911 04.09.15 Ecuador 05.09.95 SP 95-1528 20.06.97 PI 97-1158 05.09.15 Europe 04.09.95 95810545.4 07.03.01 714911 04.09.15 Finland 04.09.95 4147/95 13.10.06 117424 04.09.15 France 04.09.95 95810545.4 07.03.01 714911 04.09.15 Germany 04.09.95 69520256.1 07.03.01 714911 04.09.15 Great Britain 04.09.95 95810545.4 07.03.01 714911 04.09.15 Greece 04.09.95 95810545.4 07.03.01 714911 04.09.15 Hungary 04.09.95 2577/95 10.05.00 218284 04.09.15 India 24.08.95 1092/MAS/95 24.08.15 Ireland 04.09.95 95810545.4 07.03.01 714911 04.09.15 Israel 04.09.95 115154 14.11.00 115154 04.09.15 Italy 04.09.95 95810545.4 07.03.01 714911 04.09.15 Japan 05.09.95 227906/95 07.04.00 3054346 05.09.15 Korea-South 05.09.00 00000/05 27.11.02 364111 05.09.15 Luxemburg 04.00.00 00000005.4 07.03.01 714911 04.09.15 Malaysia 05.09.95 PI95002626 05.09.15 Mexico 04.09.95 9503785 29.03.00 195731 04.09.15 Netherlands 04.09.95 95810545.4 07.03.01 714911 04.09.15 New Zealand 04.09.95 272919 17.04.97 272919 04.09.15 Norway 04.09.95 19953457 23.02.04 316569 04.09.15 Pakistan 03.09.95 467/95 03.09.97 134791 06.09.10 Peru 04.09.95 277844 28.02.01 001736 04.09.15 Philippines 04.09.95 51237 29.10.04 1-1995-51237 29.10.21 Poland 04.09.95 P310274 00.00.00 182434 04.09.15 Portugal 04.09.95 95810545.4 07.03.01 714911 04.09.15 Russia 04.09.95 95114740 13.04.00 2156774 04.09.15 Singapore 04.09.95 9501282-9 16.11.01 50356 04.09.15 Slovak Republic 04.09.95 1088/95 04.11.03 283774 04.09.15 Slovenia 04.09.95 P9530491 07.03.01 714911 04.09.15 South Africa 06.09.95 95/7475 28.05.97 7475/95 06.09.15 Spain 04.09.95 95810545.4 07.03.01 714911 04.09.15 Sweden 04.09.95 95810545.4 07.03.01 714911 04.09.15
Date    Patent NoIssue Date Status Owner Registrations: Trademark App. No. App. Date Reg. No. Reg. Date Status Owner Applications:
Date    Patent No. EXP. DATE ------- ----------- ---------- --------- Belgium 05.01.93 1004645 19.02.11 France 20.01.95 9101993 18.02.11 Germany* 13.02.11 Great Britain 20.04.94 2241167 18.02.11 Hong Kong 10.04.97 434/97 18.02.11 Italy 15.07.94 1244496 19.02.11 Japan 15.03.02 3288055 21.02.11 Switzerland 28.02.94 683318-4 19.02.11 USA 26.09.00 6123916 26.09.17 * Germany: patent application still pending. Filing number: P4104308.1 EXHIBIT 1B Novartis Specific Patent
Date    Patent No. EXP. DATE ------- ---------- ----------- ----------- ------------ --------- Switzerland 04.09.95 95810545.4 07.03.01 714911 04.09.15 Taiwan 08.09.95 84-109395 16.08.00 114095 08.09.15 Thailand 04.09.95 27824/95 08.01.02 11623 04.09.15 Turkey 06.00.00 0000/00 22.04.02 TR199501094B 06.09.15 USA 23.04.97 09/609844 21.08.01 6277356 01.09.15 USA 23.04.97 08/842125 06.02.01 6183721 01.09.15 Venezuela 06.09.95 1572-95 08.01.99 06.09.15 Exhibit 2 Novartis Know - How 42 REF PRODUCT DATE DESCRIPTION SERIAL NO. PROTOCOL --- ------------ ---------- ---------------------------------------------------------------------- ---------- --------- 53,442 90 Y-SMT 487 08/10/2006 This Annual Report covers the period June 11, 2005 through June 142 10, 2006 (PS) 53,442 90 Y-SMT 487 04/07/2006 Request for a Type C meeting to discuss the future development of 141 OctreoTher on April 11, 2006. 53,442 90 Y-SMT 487 03/15/2006 FDA LETTER stating that NVS request for meeting, dated March 1, 2006, is premature due to FDA unanswered questions, which were discussed in the May 20, 2005 teleconference related to the drug development for OctreoTher. 53,442 90 Y-SMT 487 03/01/2006 Request for a Type A meeting to discuss the future development of 140 OctreoTher. 53,442 90 Y-SMT 487 07/29/2005 E-MAIL outlining interactions (TELECONS) between NVS and the Agency. July 29 telecon updated FDA on NVS senior management decision to seek a development partner for SMT487 and confirmed that serial no 138 should be archived for future reference. 53,442 90 Y-SMT 487 07/26/2005 This Annual Report covers the period June 11, 2004 to June 10, 2005. 139 No information. 53,442 90 Y-SMT 487 07/11/2005 TELECON with FDA to followup on discussion regarding NVS submission dated 5/16/2005 (SN 138), which responds to a request for additional information prior to making a decision on the Subpart H applicability. (86 vols, 1 CD). FDA commented that the meeting minutes as documented in email of May 24, 2005 were satisfactory and reflected the Division's thinking that the project was in Phase 1/2 development. 53,442 90 Y-SMT 487 06/16/2005 TELECON (June 15-16, 2005) with FDA concerning receipt of amendment to the orphan drug application submitted June 6, 2005. FDA left a voice-mail on June 16, 2005 confirming receipt of the amendment. 53,442 90 Y-SMT 487 05/24/2005 TELECON w/FDA to discuss the NVS submission dated 5/16/2005 (SN 138), which responds to a request for additional information prior to making a decision on the Sub...
Date    Patent No. EXP. DATE ------- ----------- ----------- --------- Australia 04.06.93 633859 04.12.09 Austria 09.12.97 403476 30.11.09 Belgium 20.11.90 1002296 05.12.09 Canada 22.02.00 2004532 04.12.09 Cyprus 01.12.95 1893 01.12.09 Denmark 30.08.04 175338 05.12.09 Finland 30.09.98 101967 11.07.14 Finland 31.12.98 102540 04.12.09 France 21.04.95 8915993 04.12.09 Germany 20.04.06 3991505 30.11.09 Great Britain 20.01.93 2225579 01.12.09 Greece 26.11.96 1002475 05.12.09 Hong Kong 21.12.95 1899/95 01.12.09 Hungary 20.09.95 211468 01.12.09 Ireland 05.12.94 62091 04.12.09 Israel 25.09.94 92534 04.12.09 Italy 19.10.93 1239285 05.12.09 Japan 10.06.05 3686503 04.12.09 Japan 05.12.97 2726320 04.12.09 Korea-South 22.07.98 156541 22.07.13 Luxemburg 18.09.91 87633 05.12.09 Malaysia 31.03.95 106120 31.03.10 Netherlands 03.04.03 194828 04.12.09 New Zealand 20.01.94 231623 04.12.09 Nigeria 13.04.93 10732 05.12.09 Pakistan 21.03.92 132014 05.12.00 Philippines 07.05.96 29649 07.05.13 Poland 28.09.93 163432 04.12.09 Portugal 20.10.95 92487 20.10.10 Saudi Arabia* 01.01.09 Singapore 15.04.97 38709 01.12.09 South Africa 28.08.91 89/9285 05.12.09 Spain 22.11.91 2023533 05.12.09 Sweden 09.11.98 8904087-7 04.12.09 Switzerland 30.08.91 678329-6 30.11.09 37
Date    Patent NoIssue Date Applicant

Related to Date    Patent No

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • Licensed Patent Rights The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of:

  • Joint Patent Rights If not already established under the Research Collaboration Agreement, prior to either Party filing any Patent Right disclosing Joint Program Technology or Joint TAP Platform Improvements, the Parties shall establish a patent committee (the “Patent Committee”) comprised of at least one (1) representative of each Party for the purpose of facilitating the preparation, filing, prosecution, maintenance and defense of Joint Patent Rights. As agreed upon by the Parties, meetings of the Patent Committee may be face-to-face or may be conducted by teleconferences or videoconferences, from time to time as needed. The Patent Committee will be the forum through which the Parties coordinate their respective obligations to each other described in Sections 5.2.2 and 5.2.3 hereof and in this Section. In the event the Parties conceive or generate any Joint Program Technology or Joint TAP Platform Improvements, the Parties shall promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon, which Party will control filing, prosecution and maintenance of such patents and how to pay for the filing, prosecution and maintenance of such patents. It is presumed that CytomX will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Program Technology or Joint Unconjugated Probody Platform Improvements, and that ImmunoGen will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint TAP Platform Improvements or Joint Conjugation Probody Platform Improvements. Neither Party will file any Joint Patent Right without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. The Party controlling filing and prosecution of any such Joint Patent Right (a) shall keep the other Party informed regarding each Patent Right, (b) shall consider in good faith any recommendations made by the other Party in regard to the filing, prosecution or maintenance of any such Patent Right and (c) shall not unreasonably refuse to incorporate any recommendations made by the other Party in regard to such filing, prosecution or maintenance.

  • Joint Patents Except as otherwise provided in this Section 7.3(b), the JSC shall entrust one Party with the right and authority, to prosecute and maintain the Joint Patents on a worldwide basis at its sole discretion herein referred to as an “Entrusted Party” (subject to this Section 7.3(b)). The Entrusted Party shall provide the other party reasonable opportunity to review and comment on such prosecution efforts regarding such Joint Patents. The Entrusted Party shall provide the other party with a copy of material communications from any patent authority regarding such Joint Patents, and shall provide the other party with drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses. If one Party (the “First Party”) determines in its sole discretion to abandon or not maintain any Patent within the Joint Patents anywhere in the world, then such Party shall provide the other Party (the “Second Party”) with thirty (30) days’ prior written notice of such determination (or such longer period of time reasonably necessary to allow the other party to assume such responsibilities) and shall provide the Second Party with the opportunity to prosecute and maintain such Patent at the Second Party’s sole expense, and if the Second Party so requests, the First Party shall assign such Patent to the Second Party (if the Second Party is Rhizen, such Patent shall be included in the Rhizen Patents or if the Second Party is TGTX, in which case such patent will be included in the TGTX Patents). If one Party (the “First Party”) desires to file, in a particular jurisdiction, a patent application that claims priority from a Patent within the Joint Patents, the First Party shall provide written notice to the other Party (the “Second Party”) of such desire. Within fifteen (15) days of such written notice, the Second Party shall provide written notice to the First Party as to whether the Second Party agrees to file a patent application in such jurisdiction or not. In the event the Second Party agrees to such a filing, the Entrusted Party shall file such patent application in such jurisdiction. In the event the Second Party does not desire to file in such jurisdiction, the Second Party shall (i) provide the First Party with the opportunity to file and prosecute such patent application and maintain any patent issuing therefrom, and (ii) assign such patent application or a right to file such patent application to the First Party; and the First Party may file such patent application in such jurisdiction at its sole expense (in which case such Patent shall be included in the respective Party’s Patents).

  • Patents and Patent Applications To the Company’s knowledge, all patents and patent applications owned by or licensed to the Company or under which the Company has rights have been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which could reasonably be expected to preclude the grant of a patent in connection with any such application or could reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Filing of Patent Applications Each Party will make timely decisions regarding the filing of Patent Applications on the CRADA Subject Inventions made solely by its employee(s), and will notify the other Party in advance of filing. Collaborator will have the first opportunity to file a Patent Application on joint CRADA Subject Inventions and will notify PHS of its decision within sixty (60) days of an Invention being reported or at least thirty (30) days before any patent filing deadline, whichever occurs sooner. If Collaborator fails to notify PHS of its decision within that time period or notifies PHS of its decision not to file a Patent Application, then PHS has the right to file a Patent Application on the joint CRADA Subject Invention. Neither Party will be obligated to file a Patent Application. Collaborator will place the following statement in any Patent Application it files on a CRADA Subject Invention: “This invention was created in the performance of a Cooperative Research and Development Agreement with the [INSERT into Agency’s model as appropriate: National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention], an Agency of the Department of Health and Human Services. The Government of the United States has certain rights in this invention.” If either Party files a Patent Application on a joint CRADA Subject Invention, then the filing Party will include a statement within the Patent Application that clearly identifies the Parties and states that the joint CRADA Subject Invention was made under this CRADA.

  • ROYALTIES AND PATENTS The Contractor shall pay all royalties and license fees. The Contractor shall defend all suits or claims for infringement of any patent rights and shall save the State harmless from loss on account thereof, except that the State shall be responsible for all such loss when a particular design, process or the product of a particular manufacturer or manufacturers is specified, but if the Contractor has reason to believe that the design, process or product specified is an infringement of a patent, The Contractor shall be responsible for such loss unless he promptly gives such information to the Architect.

  • INFRINGEMENT AND PATENT ENFORCEMENT 11.01 PHS and Licensee agree to notify each other promptly of each infringement or possible infringement of the Licensed Patent Rights, as well as any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either Party becomes aware. 11.02 Pursuant to this Agreement and the provisions of Chapter 29 of title 35, United States Code, Licensee may: a) bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid claims in the Licensed Patent Rights; b) in any such suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature recoverable for such infringement; and c) settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that PHS and appropriate Government authorities shall have the first right to take such actions. If Licensee desires to initiate a suit for patent infringement, Licensee shall notify PHS in writing. If PHS does not notify Licensee of its intent to pursue legal action within forty five (45) days, Licensee will be free to initiate suit PHS shall have a continuing right to intervene in such suit. Licensee shall take no action to compel the Government either to initiate or to join in any such suit for patent infringement. Licensee may request the Government to initiate or join in any such suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any such suit at the request of the Licensee, Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of such motion or other action, including any and all costs incurred by the Government in opposing any such motion or other action. In all cases, Licensee agrees to keep PHS reasonably apprised of the status and progress of any litigation. Before Licensee commences an infringement action, Licensee shall notify PHS and give careful consideration to the views of PHS and to any potential effects of the litigation on the public health in deciding whether to bring suit. 11.03 In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Licensed Patent Rights shall be brought against Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by Licensee under Paragraph 11.02, pursuant to this Agreement and the provisions of Chapter 29 of Xxxxx 00, Xxxxxx Xxxxxx Code or other statutes, Licensee may: a) defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the Licensed Patent Rights; b) in any such suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of whatever nature recoverable for such infringement; and c) settle any claim or suit for declaratory judgment involving the Licensed Patent Rights-provided, however, that PHS and appropriate Government authorities shall have the first right to take such actions and shall have a continuing right to intervene in such suit. If PHS does not notify Licensee of its intent to respond to the legal action within a reasonable period; which period shall not exceed ninety (90) days, Licensee will be free to do so. Licensee shall take no action to compel the Government either to initiate or to join in any such declaratory judgment action. Licensee may request the Government to initiate or to join any such suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any such suit by motion or any other action of Licensee at the Licensee’s request, Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of such motion or other action. If Licensee elects not to defend against such declaratory judgment action, PHS, at its option, may do so at its own expense. In all cases, Licensee agrees to keep PHS reasonably apprised of the status and progress of any litigation. Before Licensee commences an infringement action, Licensee shall notify PHS and give careful consideration to the views of PHS and to any potential effects of the litigation on the public health in deciding whether to bring suit. 11.04 In any action under Paragraphs 11.02 or 11.03, the expenses including costs, fees, attorney fees, and disbursements, shall be paid by Licensee. The value of any recovery made by Licensee through court judgment or settlement shall be treated as Net Sales and subject to earned royalties. Any and all costs incurred by the Licensee in defending the Licensed Patent Rights, as provided above, shall be deducted from Net Sales. 11.05 PHS shall cooperate fully with Licensee in connection with any action under Paragraphs 11.02 or 11.03. PHS agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by Licensee.

  • NOTICE AND ASSISTANCE REGARDING PATENT AND COPYRIGHT INFRINGEMENT The provisions of this clause shall be applicable only if the amount of this Agreement exceeds $100,000. (a) The Contractor shall report to the Government through BSA promptly and in reasonable written detail, each notice or claim of patent or copyright infringement based on the performance of this Agreement of which the Contractor has knowledge. (b) In the event of any claim or suit against the Government on account of any alleged patent or copyright infringement arising out of the performance of this Agreement or out of the use of any supplies furnished or work or services performed hereunder, the Contractor shall furnish to the Government when requested by the Government or BSA, all evidence and information in possession of the Contractor pertaining to such suit or claim. Such evidence and information shall be furnished at the expense of the Government except where the Contractor has agreed to indemnify the Government or BSA. (c) This clause shall be included in all subcontracts.